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Abstract
Schizophrenia is a major mental illness which for a long time has been 
considered to have both genetic and environmental aspects to its aetiology. In 
recent years, genetic studies of schizophrenia have suggested that the long arm 
of chromosome 1 is a major candidate region for susceptibility loci for this 
complex disorder. With a number of research groups having reported some 
evidence of linkage or association at 1q21-24, 1q32.2-41, or 1q42. Although the 
data from all the implied chromosomal loci for schizophrenia are not consistent, 
the findings for chromosome 1q are amongst the most replicated across various 
study populations. 
Initially 1q42 was identified as a potential site for a schizophrenia susceptibility 
locus in a large Scottish family, containing a wide spectrum of major mental 
illnesses, where a balanced (1;11)(q42.1;q14.3) translocation was found to co-
segregate with schizophrenia and other related psychiatric disorders. Two novel 
overlapping genes located on the opposing DNA strands were found to be 
directly disrupted by this translocation, and were subsequently named Disrupted 
in Schizophrenia 1 and 2 (DISC1 and DISC2). Linkage analysis carried out in 
Finnish schizophrenia families confirmed the 1q42 locus and the DISC genes as 
good positional candidates for susceptibility to schizophrenia, when a lod
max
 of 
3.2 was observed for a microsatellite located intragenic of DISC1.
In the studies performed here the initial linkage finding on 1q42 was verified 
through its replication in an independent sample of families from Finland. This 
locus was further investigated using SNPs and their haplotypes, monitoring for 
transmission disequilibrium to affected individuals in the entire population of 
458 Finnish families. This analysis highlighted four restricted genomic regions 
that significantly associate with schizophrenia. Amoung these, the most robust 
finding is the associated allelic haplotype that spans from intron 1 to exon 2 of 
the DISC1 gene (HEP3 haplotype), and was found to be significantly under-
transmitted to affected females. 
The haplotype was used to further dissect the role of DISC1 in the aetiology of 
schizophrenia, and it was found that the association was mainly to qualitative 
trait-components representing delusions, hallucinations, and negative symptoms 
of schizophrenia. In using quantitative traits that represent endophenotypes of 
schizophrenia, it was found that the haplotype associated mainly to visual 
working memory functions. This association was between HEP3 and poorer 
performance in visual working memory, particularly in males, leading to the 
analysis of a control sample, representative of the general Finnish population.  
This enabled the re-evaluation of the previously observed under-transmission to 
affected females as an epiphenomenon caused by the higher frequency of HEP3 
in the Finnish families ascertained for schizophrenia. Consequently, the data 
points to HEP3 representing a variation that is associated with higher risk to 
schizophrenia in males and suggests that it functions through a mechanism 
affecting visual working memory. 
Since schizophrenia is known to be a polygenic disorder it was of interest to 
analyse which genomic regions may be linked to schizophrenia when 
simultaneously accounting for the effect of DISC1. A genome scan was 
performed on two HEP3 stratified samples, with three linkage peaks (lod > 3) 
being observed. One was the original 1q42 locus containing DISC1, while the 
other two represented a region previously significantly linked to schizophrenia 
(10q21) and a locus (16p13) containing a DISC1 interacting gene (nuclear 
distribution gene E homolog 1, NDE1). Among the peaks displaying suggestive 
lod scores, six loci were identified in regions previously linked to schizophrenia, 
including the loci for the candidate genes dysbindin (DTNBP1), neuregulin 1 
(NRG1), glutamate receptor metabotrophic 3 (GRM3), and reelin (RELN). Of 
main interest though was the identification of a locus containing a DISC1
interacting gene, NDE1, as it highlights the pathway these two genes act along 
for a role in schizophrenia. NDE1 was further analysed and found to associate to 
schizophrenia, the risk allele being significantly associated with affected 
females. Suggesting that a DISC1 “pathway” is involved in the aetiology of 
schizophrenia in the Finnish population 
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81 Introduction
Schizophrenia is a severe mental disorder affecting approximately 1% of the 
worldwide population. The disorder is considered to be partly genetic in 
aetiology, with family11, twin12, and adoption15 studies suggesting a considerable 
high heritability, estimated to be as high as 83% based on the analysis of a 
Finnish twin cohort12.
Finland is one of the best characterized populations considered as relatively 
isolated and the established frequency of known disease mutations reflects the 
history of multiple bottlenecks16. This population history and the presence of 
extensive genealogical records make the Finnish population valuable for studies 
of genetic disorders. To date 36 diseases have been identified as enriched in the 
population, and are often referred to as the Finnish disease heritage17,18. It is 
hypothesised that the same events in the population history which led to this 
enrichment could also result in an increased homogeneity of the disease alleles 
underlying more complex disorders like schizophrenia18-20.
The research presented here used three advances that have led to huge leaps in 
the genetic analysis of complex traits. The completion of the Human Genome 
Project has produced genome-wide information that can be analysed thoroughly 
in silico, providing tools for efficient genome-wide analysis and directing the 
further analyses to be performed. Improvements in high throughput genotyping 
now means that typing large numbers of markers, in samples of large enough 
size to give the power to detect association, is no longer cost prohibitive. Lastly, 
there have been advances in the statistical programs used for analysing such 
large amounts of data robustly. These three were applied to the analysis of the 1q 
genomic locus in a sample of Finnish families with a high density of 
schizophrenia, which was established to contain potential susceptibility genes 
through prior genetic analysis of schizophrenia. Furthermore, these techniques 
were applied to the continuation of the analysis, by dissecting the role of the 
16p13 region in schizophrenia, a locus highlighted by linkage analysis 
conditioned on 1q42. 
92 Review of the literature 
2.1 Overview of schizophrenia 
2.1.1 Diagnosis
Schizophrenia is a heterogeneous disorder identified on the basis of a pattern of 
abnormal behaviours, characterised by false beliefs and abnormal perceptions, 
which are reflective of the differentiation between inner preconceptions and 
expectations from external stimuli. However, a number of other symptoms can 
also present with diagnosis being dependent on the quantity, severity and 
duration of these symptoms. 
Hippocrates (460-377B.C.) described epilepsy, mania, and depression, which he 
correctly attributed to the brain. However, few ancient texts are found to 
describe schizophrenia, yet upon adequate description of the disorder in 1809 the 
disease became more visible over the western world and numbers of sufferers 
increased rapidly for a hundred years21. Nowadays schizophrenia is one of the 
best known and most common forms of mental illness, yet its true origins remain 
a mystery. 
These first adequate descriptions of schizophrenia were made independently in 
England and France, by John Haslam (1764-1844) and Philippe Pinel (1745-
1826) respectively. Yet, it is Emil Kraepelin (1856-1926) who is so often 
credited, due to his definitive work in categorising the disorder and in naming it 
dementia praecox. Most of Kraeplein’s clinical analyses of schizophrenia still 
stand as the descriptive terms used today21.
Modern day schizophrenia can currently be diagnosed according to two 
methods, the Diagnostic and Statistical Manual for Mental Disorders currently in 
its forth edition (DSM-IV)28 (Table 1), and the International Classification of 
Diseases, now in its tenth edition (ICD-10)29. The two classification systems do 
concur and essentially only differ in their semantics21. In Europe both methods 
can be used for clinical and research work, yet the ICD-10 predominates in the 
clinical field and the DSM-IV in the research field. 
10
Table 1 
DSM-IV diagnostic criteria for schizophrenia 
A. Characteristic symptoms: Two or more of the following, each present for a 
significant portion of time during a 1-month period (or less if successfully 
treated):
1. Delusions 
2. Hallucinations 
3. Disorganized speech 
4. Grossly disorganized or catatonic behaviour 
5. Negative symptoms 
Only one Criterion A symptom is required if delusions are bizarre or 
hallucinations consist of a voice keeping up a running commentary on the 
person’s behaviour or thoughts, or two or more voices are conversing with 
each other. 
B. Social/occupational dysfunction: for a significant portion of the time since 
the onset of the disturbance, one or more major areas of functioning such as 
work, interpersonal relations, or self-care are markedly below the level 
achieved prior to the onset (or, when the onset is in childhood or adolescence, 
failure to achieve the expected level). 
C. Duration: Continuous signs of the disturbance persist for at least 6 months, 
of which at least one month should be of symptoms that meet Criterion A. 
The 6 months may include periods of prodromal and residual symptoms. 
D. Schizoaffective and mood disorder exclusion: Schizoaffective disorder 
and mood disorder with psychotic features have been ruled out because either 
no major depressive, manic, or mixed episodes have occurred concurrently 
with the active-phase symptoms, or if mood episodes have occurred during 
active-phase symptoms, their total duration has been brief relative to the 
active and residual periods. 
E. Substance/general medical condition exclusion: The disturbance is not due 
to the direct physiological effects of a substance or a general medical 
condition.
F. Relationship to a pervasive developmental disorder: if there is a history of 
autistic disorder or another pervasive developmental disorder, the additional 
diagnosis of schizophrenia is made only if prominent delusions or 
hallucinations are also present for at least a month (or less if successfully 
treated).
There are a number of other psychiatric disorders that present with partially 
similar symptoms to schizophrenia30, and it is common to observe these 
disorders in families where a schizophrenia affected individual has already been 
identified. This leads to the hypothesis that these disorder symptoms are in a 
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continuum, rather than being distinct disorders, suggesting that there will be 
some common genes underlying psychoses that fall into separate diagnostic 
classes of the classification system. 
2.1.2 Epidemiology 
To understand a disorder like schizophrenia it is necessary to quantify it in a 
number of ways that allow for the identification of the natural characteristics of 
the disorder. Primarily, these are the morbid risk (likelihood of someone 
suffering an episode of schizophrenia during their life), incidence (number of 
new cases of schizophrenia usually given in a period of one year and in a 
population of 100,000), and prevalence (total number of living people who have 
been diagnosed with the disorder). Although schizophrenia is a global 
phenomenon such measures differ between the population samples studied, for 
example the prevalence of the disorder can range from 0.3 per 1,00035 to 22 per 
1,00036. Such variations can be observed between countries, municipalities or 
districts, and between urban and rural areas37. However, it is widely stated that 
schizophrenia has a global morbid risk of about 1%, and while individuals with 
schizophrenia generally have a decreased reproduction rate38 the prevalence 
seems to be relatively stable over time. One such hypothesis for this stability is 
that the genetic variations involved in the aetiology are relatively common as 
they may provide an advantage to the individual (for review see39).
On the whole schizophrenia is equally prevalent in men and women, although 
some studies do report a higher prevalence in males36,45,46. There are some sex 
differences with regard to the prognosis of the disorder with men on average 
having an earlier onset and more severe course to the disorder. The peak for men 
is in the early twenties, while for women it is in the mid to late twenties with a 
second peak around the time of menopause47.
Family11, twin12 and adoption15 studies have shown that there is a highly genetic 
aetiology to schizophrenia. This genetic epidemiology is discussed in detail 
later. Despite the high genetic risk there is also a strong risk from environmental 
factors, with risks caused by genetic and environmental interactions often being 
included with the genetic risk. Numerous environmental risk factors have been 
identified for schizophrenia, with the most widely regarded including obstetric 
complications leading to foetal hypoxia52,53, infections during pregnancy55-57,
urban birth and upbringing58, and heavy cannabis use during adolescence59.
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2.1.3 Clinical features 
Schizophrenia is a complex phenotype, consisting of many symptoms, some of 
which do not need to be present in order to meet the diagnostic criteria. 
Therefore, the clinical presentation of the disorder within a population of 
affected individuals is highly heterogeneous. This can obscure the potential 
effect of some loci when analysis is performed to search for linkage or 
association with schizophrenia in such populations, leading to many false 
negative results being observed. This can also be due to the fact that the effect of 
genetic variation can be obscured by other biological mechanisms that are acting 
on the disorder (Figure 1). 
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Figure 1 
An oversimplified schematic presentation of the processes that lead from genes to the end-state diagnosis in a complex 
genetic disorder. In actuality it is likely that many genes, some of which will interact with each other, will act on each 
biological mechanism, and that these mechanisms potentially interact together and provide liability to possibly many of 
the clinical features that make up the end state diagnosis. Additionally, the environment could provide further risks, or 
interact with any of the stages presented here. 
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One approach to address the complexity of the clinical phenotype, not 
necessarily reflecting the biological background of the disease, is to use clinical 
features as intermediate phenotypes, whose relationship to specific molecular 
pathways might be more direct. These can be either trait components or 
endophenotypes, which only differ in their relation to the disorder of interest. 
Trait components are generally dependent on the disorder and serve as an aid to 
making the studied phenotype more homogenous. For example a particular 
symptom of schizophrenia, like auditory hallucinations, can be used. This trait 
would not generally be present if the individual was not affected, yet not all 
individuals with schizophrenia present that trait. Importantly, even if a person 
without the disorder of interest has a symptom that is used as a trait component 
they will not be classified as affected if the main diagnosis is not present. In 
contrast an endophenotype is an independent trait that is associated with the 
disorder. In the case of schizophrenia working memory can be used as an 
example of an endophenotype. Everyone has a degree of working memory, yet it 
has been shown that individuals with schizophrenia on average perform worse 
on tasks requiring this function. The purpose to using such traits is that their 
molecular background is likely to be more straightforward, with less genetic 
heterogeneity contributing to the variation in the trait, when compared to the 
diagnostic phenotype of schizophrenia65,66. This is summarised in the five criteria 
for what constitutes an endophenotype; 1) it is associated with illness in the 
population, 2) it is heritable, 3) primarily state-independent, 4) co-segregates 
with illness in families, and 5) unaffected family members of affected 
individuals have a higher rate of the endophenotype than the general 
population65. In order to be provide more power to genetic analysis a sixth 
criterion can be added that specifies that the endophenotype be a quantitative 
measure. 
For schizophrenia trait components can be derived, for example, from the 
Operational Criteria Checklist for Psychotic Illness (OCCPI), as used in II, 
which is a series of 90 items representing life history and symptomatology69,70
which can be systematically checked if a feature is present, creating an 
individual profile for each presenting proband. Prominent candidate 
endophenotypes are measures of the structure and function of the brain. These 
can be traits representative of cognitive functions as used in III and IV, but can 
also be derived from electrophysiological and structural and functional imaging 
of the brain. In a practical sense, it can be hypothesized that the use of more 
informative quantitative traits, if truly associated with clinical vulnerability and 
the studied gene variations, has the potential to display stronger association with 
the genetic markers, than the end-state diagnosis. 
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Endophenotypes of schizophrenia have previously proven to be successful in 
determining more about the relation between the finding of the cholinergic 
receptor, nicotinic, alpha polypeptide 7 (CHRNA7) gene association and 
schizophrenia. When it was observed that the gene associates to deficits in the 
mechanism that underlies the subconscious ability to gradually gate the response 
to a repeated stimulus71, sensory gating. This is represented by the characteristics 
of the P50 evoked potential which normally decreases upon reoccurrence of a 
stimulus, yet stays at its original intensity in the brains of individuals with 
schizophrenia and their unaffected relatives72.
2.2 Genetics of schizophrenia 
2.2.1 General aspects 
It has long been thought that schizophrenia has a partly genetic aetiology, but it 
was only through family, twin and adoption studies that this hypothesis gained 
credibility.
Large numbers of studies have shown that schizophrenia runs in families, as the 
morbid risk of developing schizophrenia increases with the greater genetic 
relatedness to an individual with the disorder (Table 2)73. It has also been shown 
that the number of affected siblings an individual has increases their risk of 
developing schizophrenia. When an epidemiological study was carried out in 
Finland, it was observed that the morbid risk of schizophrenia to individuals was 
4.2%, 6.4%, and 8.7% given 1, 2, or 3, affected siblings respectively36. However, 
family evidence is not enough to prove a genetic aetiology to a disorder as 
families generally share much of their environment as well. 
Twin studies go some way to addressing the matter of elucidating the 
contribution of genes to the disorder. With a higher concordance of 
schizophrenia between monozygotic twins (48%) than between dizygotic twins 
(17%)12,74 suggesting a clear contribution to the aetiology from genetics. 
Although this method has some drawbacks, the method can not account for 
differences in the way mono- and di-zygotic twins are treated similarly, it can 
not separate the effects of genetics from those of a shared in utero environment, 
and it can not account for gene expression differences between the twins. 
To better account for the environmental issues that are involved in the aetiology 
of schizophrenia it is necessary to perform adoption studies. Such studies have 
found that there was increased risk of schizophrenia in the biological relatives of 
an adopted affected individual yet no increase in risk was observed for the 
adoptive relatives15,75,76.
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Twin studies have also played a role in determining the heritability of 
schizophrenia, and thereby stating what fraction of the disorder can be said to be 
due to genetic factors. In a Finnish study, such an estimate of heritability was 
made to be as high as 83%, with the remaining 17% being due to non-shared 
environmental factors12, such as cannabis smoking by one twin and not the other. 
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Table 2 
Morbid risk of schizophrenia depending on genetic relatedness to an affected 
individual, adapted from Tsuang 200073.
Relationship Shared Genes Morbid Risk (%) 
General Population NA 1 
Spouse of Patients NA 2 
Third-Degree Relatives 12.5  
   First Cousins  2 
Second-Degree Relatives 25  
   Uncles/Aunts  2 
   Nieces/Nephews  4 
   Grandchildren  5 
   Half-Siblings  6 
First-Degree Relatives 50  
   Parents  6 
   Siblings  9 
   Children  13 
   Sibling with 1 affected parent  17 
   Dizygotic twin  17 
Monozygotic twin 100 48 
Children with 2 affected parents 100 46 
NA, not applicable 
2.2.2 Previous genetic findings for schizophrenia 
Genetic studies of schizophrenia have been carried out for many decades, but it 
has only been since the turn of the millennium that consistent linkage findings 
for schizophrenia have been identified and independently replicated, giving a 
solid basis for further analysis of the regions with regard to identifying 
hypothetical candidate genes. Such linkage results came from genome-wide 
scans, and through the identification of chromosomal rearrangements in large 
pedigrees, and have led to several consensus loci being identified, many of 
which have had potential predisposing genes identified at or close to the linked 
regions: 1q21-22 (regulator of G-protein signalling 4, RGS4; C-terminal PDZ 
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domain of neuronal nitric, CAPON)77-80, 1q42 (disrupted in schizophrenia 1, 
DISC1)3-9,81,82, 5q (gamma-aminobutyric acid, GABA, receptor cluster and EPSIN 
4)14,80,83-88, 6p23 (dysbindin, DTNBP1)22-26,89-93, 8p22-p11 (neuregulin 1, NRG1)41-
43,91,94
, 13q32 (D-amino acid oxidase activator, G72/DAOA; hypothetical protein 
G30, G30)41,54,95,96, and 22q11-q13 (catchecol-O-methyltransferase, COMT;
praline dehydrogenase 1, PRODH)97-104. The numerous inconsistent linkage 
findings for schizophrenia are thought to be due to the heterogeneity of the 
disorder and the diversity of the populations being analysed. However, a recent 
meta-analysis of genome scans suggests that some loci may contribute to 
schizophrenia in many or most populations, with loci whose effects are strongly 
detected in a unique population potentially being relevant to other populations2.
This is coming to light more and more as a number of these genes are replicated 
for association in independent samples from around the world. The most 
consistently replicated so far have been the NRG1 and DTNBP1 genes. In 
addition to these genes identified by consistent linkage peaks many genes are 
being identified as associated to the disorder by being identified as good 
candidates by other means, such as expression analysis (Table 3). 
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Table 3 
Genetic evidence for each current candidate gene for schizophrenia and related disorders, updated and adapted from 
Harrison and Weinberger 20051.
Strength of evidence is arbitrarily represented by a number of + signs, 
representative of the number of independent replications for that finding. 
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2.2.3 Chromosome 1q in schizophrenia 
Chromosome 1q has emerged as one of the most likely regions in the genome 
for containing schizophrenia susceptibility loci (Figure 2). In Canadian families, 
a lod score of 6.5 has been reported on 1q21 between markers D1S1653 and 
D1S167977. Some 10 cM telomeric from this location at 1q24, evidence of 
linkage between the trait and a polymorphic genetic marker displayed a  
logarithm of odds (lod; described in detail later) score of 3.280 in a British-
Icelandic study sample around the marker D1S196. Further towards the 1q 
telomere, a haplotype of markers spanning the 1q32-q41 locus was identified by 
a study of an internal isolate population of Finland105. The markers from this 
haplotype were then genotyped in a case-control Finnish twin sample for 
schizophrenia with extensive neuropsychological data. The most telomeric of 
these markers at 1q41 displayed the strongest association to quantitative 
measures of visuospatial working memory and visual attention106. Also, in a 
family set ascertained for schizophrenia a genome-wide scan using a number of 
quantitative traits of cognitive functions observed some evidence of linkage (lod 
> 1.5) to verbal memory functions at the 1q41 locus10. However, it is a proximal 
location to this, 1q42, which has recently been developing as one of the most 
consistently replicated loci. 
Initially 1q42 was identified as a potential site for a schizophrenia susceptibility 
locus in a large Scottish family, containing a wide spectrum of major mental 
illnesses, where a balanced (1;11)(q42.1;q14.3) translocation was found to co-
segregate with schizophrenia and other related psychiatric disorders3. Two novel 
genes were found to be directly disrupted by this translocation, and were 
subsequently named Disrupted in Schizophrenia 1 and 2 (DISC1 and DISC2)107.
When other Scottish families ascertained for schizophrenia and bipolar disorder 
were used to monitor for association between common bi-allelic variations of 
one base pair found throughout the genome (single nucleotide polymorphisms or 
SNPs) in the DISC genes and the disorder, no significant association was 
observed108. Later, linkage findings within a Finnish schizophrenia nuclear 
family sample confirmed the 1q42 locus and the DISC genes as good positional 
candidates for susceptibility to schizophrenia, when a lod
max
 of 3.2 was observed 
for a microsatellite located within the DISC1 gene7.
Two large studies have failed to find support for any schizophrenia susceptibility 
locus on chromosome 1q. Initially, a multi-centre meta-analysis of all genome-
wide scans of schizophrenia was performed, pooling linkage peaks rather than 
the original genotype information2, chromosome 1q was not among the 
interesting loci, specifically the bin containing 1q42 represented the 46th bin 
among 120. However, a wide region spanning 1p13.3 to 1q23.3 was highlighted 
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in this study as a suggestive site for a schizophrenia locus (loci). The 
involvement of 1q in schizophrenia has also been challenged in a large multi-
centre replication study with 984 schizophrenic sib-pairs. In total, 16 
microsatellite markers, covering approximately 110 cM on 1q, were analyzed 
and no evidence of linkage was obtained109. Yet, the validity of the tests 
performed within these studies has been challenged110,111. One of the main 
weaknesses when using meta-analysis and multi-centre studies is that despite the 
increased sample size you also increase the genetic heterogeneity underlying the  
disorder, as such methods generally involve the use of many different sample 
populations of different ethnic origins. Such issues of genetic heterogeneity, 
incomplete penetrance and phenocopies are concerns that surround the whole of 
genetic research into complex disorders112 and are thus exaggerated when using 
samples obtained from many different populations. Furthermore, meta-analyses 
also escalate many problems and biases of the initial studies, including how the 
diagnostic criteria were adapted, and the inheritance models used in the analysis. 
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Figure 2 
Diagram to show the relative locations of linkage (above) and association (below) observations on chromosome 1. 
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2.3 Strategies for mapping genes for complex disorders 
In order to identify putative genes that underlie the aetiology of a complex 
disorder, a series of steps (Figure 3) are generally considered as the ideal way to 
proceed. Conventionally this starts with a whole genome scan that analyses 
hundreds of highly polymorphic genetic variations in the form of microsatellite 
markers from every region of the genome to identify large genomic regions that 
show co-segregation with the disorder in families or sibling pairs. Due to 
uncertainties in the parameters adapted in linkage analysis it is likely that a 
number of loci will be identified that are still very wide. Therefore, a dense or 
fine map is produced on the loci and genotyped in families in order to narrow 
down the critical DNA region. If linkage is constantly observed within the locus, 
analysing candidate genes is the next logical step, initially looking for 
association between intragenic and flanking SNPs and their haplotypes 
(described in full later). Certain priority is typically given in these analyses to 
genes biologically relevant for the studied disorder, such as neurotransmitter 
receptor genes in the case of schizophrenia. Genome-wide gene searches are 
often complimented with linkage and association studies of markers within or 
flanking functional candidate genes. 
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Figure 3 
Illustration of the common three step strategy employed in genetic analysis to 
identify genomic regions of interest. White boxes provide the terms used to 
describe the analysis performed, and black boxes show the resolution provided 
at each step. 
2.3.1 Statistical methods 
2.3.1.1 Dichotomised trait analysis 
2.3.1.1.1  Linkage analysis 
Linkage analysis measures whether or not transmission of a certain region of a 
chromosome is non-random and dependent on the affection status of the disorder 
in question. In practice this analysis looks at the segregation of allelic variants of 
many microsatellite markers that are highly polymorphic exposing numerous 
alleles in the population. This is either done on a sparse genome-wide level, or 
on a fine/dense level of a region already of interest to the disorder. Then using a 
sample of families multiply affected by the disorder, statistical analyses are used 
to test if a particular allele of a particular marker segregates with the disorder at 
a greater frequency than by chance, in each individual family. This is repeated 
assuming a number of different recombination fractions between the marker and 
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the disease locus. Each marker is then given a logarithm of odds (lod) score for 
linkage for each family, which is then accumulated over the sample to produce 
an overall lod score for each recombination fraction113,114. The lod score is most 
often maximised over recombination fractions to produce a lod
max
 for each 
marker. For monogenic disorders the recombination fraction at which the lod
max
occurs is indicative of the distance between the marker and the susceptibility 
gene, but in disorders with a complex genetic inheritance this property is largely 
ignored because the specified model for inheritance used in statistical analyses is 
often false or over simplified. 
In the statistical analysis for significant deviation from chance, the high number 
of markers introduces the risk of type I errors (false positives). This high number 
has typically been around 300 when microsatellites have been used, but in the 
dawning age of genome-wide association analysis hundreds of thousands of SNP 
markers115 are to be genotyped and analysed. It was necessary for guidelines to 
be made as to what constitutes a significant deviation from chance. With such 
guidelines for genome-wide analysis with microsatellites (Table 4) being set by 
Lander and Kruglyak in 1995, and are still generally adhered to today116.
However, these will need revision to account for the increased scale of the new 
genome-wide association analyses. 
Linkage analysis has been used for many years in the studies of complex genetic 
traits. Performing a genome-wide linkage scan has become a staple ingredient in 
all genetics departments worldwide. Yet such analysis comes with a heavy 
drawback, it is just the starting place for genetic analysis, so any observations of 
significant linkage implies a large region of the genome for further analysis, 
rather than yielding putative susceptibility genes straight away. Such further 
analysis could be futile if the original observed linkage was in fact a false 
positive, therefore it is considered necessary for independent replication of a 
locus to be observed, in order to substantiate the original finding. Such 
replication provides a more solid basis for the further analysis of linked genomic 
loci. In schizophrenia many genomic loci have been implicated by linkage 
analysis, but only a few of these linked regions have been consistently seen to be 
linked to the disorder in independent samples117. These regions have since been 
analysed for association to the disorder, with greater success than in regions 
where no consistent linkage was first observed. 
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Table 4 
Linkage Guidelines 
Suggestive Linkage expected to occur one time at 
random in a genome scan 
Significant Linkage expected to occur 0.05 times in a 
genome scan 
Highly Significant Linkage expected to occur 0.001 times in a 
genome scan 
Confirmed Linkage expected to occur 0.01 times in a 
genome scan, when performed in a 
subsequent independent sample 
2.3.1.1.2  Association analysis 
Association analysis simply measures whether or not a certain allele of a 
particular gene locus is found in affected individuals with significantly different 
frequency than in non-affected individuals over an entire sample set. Association 
studies primarily use SNPs as they are more common throughout the genome 
than microsatellite markers, yet when studied individually they suffer from low 
information content as bi-allelic markers. However, almost five million SNPs 
are to date identified and validated within the human genome, with this number 
expected to rise to around ten million, providing an excellent basis for haplotype 
construction, resulting in combinations of markers with higher information 
content. Haplotypes are defined as combinations of alleles from nearby DNA 
polymorphisms that are inherited as a block from a common ancestor. Typically, 
after linkage analysis has identified candidate regions, multiple SNP markers, of 
which it is hypothesised some will be in a degree of linkage disequilibrium (LD) 
with the functional mutation, are genotyped and analysed. LD means the non-
random association between alleles of closely linked markers, and measures if 
co-occurrence of a certain sequence variation with another variation at another 
locus differs from chance. LD is complete when the information deduced from 
one variation fully correlates with the information from the other. It has been 
shown that significant LD between SNP pairs can be seen up to 0.1 cM, varying 
between populations, the longer regions of LD being observed in relatively 
isolated populations like those found in Finland118. Such isolated populations, 
showing wider LD intervals, would be ideal for performing association 
analysis19.
The fundamental idea to utilize haplotypes on chromosomal regions identical in 
siblings through inheritance from the same parent (identical by descent; IBD) 
and LD between markers in IBD alleles in population isolates is the assumption 
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of a founder effect where individuals affected with the disorder share a genomic 
region originating from a common ancestor. Due to this, allelic heterogeneity is 
minimised and a smaller sample size would thus be sufficient to detect the locus. 
However, in complex disorders, like many psychiatric illnesses, it would be 
expected that the common ancestor is far more distant, and that there are a 
number of divergent founder alleles being inherited. This means that the shared 
region or regions between affected individuals would be considerably smaller 
and heterogeneous than those for monogenic disorders, and thus locus 
identification by LD remains a challenge for complex disorders. 
Association analysis in complex traits is greatly benefiting from the 
developments in the analysis programs and packages that can be used with 
regard to haplotypes. Until recently SNP haplotypes could not effectively be 
analysed for association. The individual SNPs could be placed into haplotypes 
by programs like GENEHUNTER119 and SIMWALK120, but such programs are 
unable to fully cope with multiple tightly linked SNPs and the LD between 
them121, and are highly dependent on the quantity122 and quality of genotype 
information being used. Consequently, they are best suited to calculating 
haplotypes for microsatellite markers in large family-based sample where both 
parents and offspring are genotyped. The development of genotype error 
checking programs that can check for Mendelian123 and non-Mendelian124 errors, 
and of haplotype analysis programs like TRANSMIT125 and haplo-FBAT126 has 
greatly advanced haplotype-based association studies. The error checking 
programs now mean that the raw data being analysed is of a reliable quality, 
which the haplotype programs can then use to estimate the haplotypes for each 
person even if some parental information is missing, which can then be analysed 
for transmission distortion with the disorder. Programs that can reliably calculate 
the haplotypes in population based analysis have also been developed127 enabling 
testing of association using haplotypes in various study designs. 
2.3.1.2 Quantitative trait analysis 
Both linkage and association analysis programs traditionally use dichotomised 
traits which classify individuals in the analysis as either affected or unaffected, 
with the additional option of individuals being classified as unknown. Recently, 
newer programs, like Merlin128 and QTDT129, are starting to be able to analyse 
traits that are continuous variables for both linkage and association. The classic 
examples of such traits are height and weight, but variables can also be collected 
from tests of neurocognitive functions, which are deficient in individuals with 
schizophrenia and their relatives when compared to a control population130.
Using such traits in the analysis of complex disorders provides a beneficial 
increase in the power to detect linkage or association. This is partly due to these 
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traits most likely being endophenotypes of the disorder in question, and 
therefore being representative of traits closer to the biological function 
controlled by genes (Figure 4, and discussed earlier). However, using 
quantitative variables on there own increases the power, for the simplest reason 
that such variables contain more information than dichotomised versions of the 
same traits. Yet this power can be diminished as, in family samples that have 
been ascertained for a high number of affected individuals, the variability of the 
quantitative trait in the study sample is often reduced. 
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Figure 4 
Schematic to show the difference between testing for genetic association with an end-state diagnosis, above arrow, 
compared to analysing with an endophenotype, below arrow. The illustration assumes that the endophenotype would be 
more directly associated with the changes in biological pathways than the end-state diagnosis. As in Figure 1 the 
interactions are likely to be more complex, with many genes affecting a single endophenotype, which in turn can be 
present for more than one disorder. 
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2.3.2 Statistical significance 
Despite the recent advances in genetic tools and analytical methods in complex 
disorder research, there is one main inherent disadvantage, multiple testing. In 
both the original linkage analysis and in association analysis many hundreds of 
tests are performed and with each test there is an increase in the chance of 
observing a type I error (false positive) which needs to be corrected for. For 
linkage analysis the standard way of correcting for this multiple testing is 
primarily to establish criteria as to what can be deemed as a significant finding 
from a genome-wide scan (mentioned earlier). In the case that a genome-wide 
scan has been performed under an extra bias that will affect the analysis, as in 
IV, it is common place to use simulations of the data to address the real 
statistical significance of the findings. 
The robust standard for corrections adapted in statistical genetics is the 
Bonferroni correction for multiple testing, in which the observed p-value is 
multiplied by the number of independent tests performed. In genome-wide 
marker and haplotype analysis, this can mean possibly thousands of tests 
practically negating any finding which may be observed. However, for such 
haplotype analysis these corrections may be overly conservative as each test is 
not entirely independent as the SNPs being used are to some degree in LD131.
Alternatively, an empiric p-value can be derived using permutation analysis for 
the tests performed, using the sample to simulate the analysis performed many 
times and thus providing an estimation of the statistical significance for the 
observation, by indicating how likely the observed result was to occur purely by 
chance. However, this is still not ideal as the empiric p-value is dependent upon 
the arbitrarily chosen number of permutations to be carried out by the researcher. 
This is illustrated from the analysis of the G72/G30 genes with schizophrenia by 
Chumakov et al54, where an original 20, 000 permutations provided a number of 
haplotypes displaying significant association, yet after a further 50, 000, 000 
permutations only two haplotypes remained significant. So rather than perform 
such corrections and risk type II errors (false negative), it is common place to 
rely on independent replication in multiple study samples to verify the initial 
genetic findings. 
This then poses a Catch-22132 study design conundrum for future analysis, where 
the one method that can be used to achieve a goal, paradoxically makes that goal 
unobtainable. In this instance, to avoid multiple testing only the one test directly 
replicating the original observation should be performed. However, 
schizophrenia and other psychiatric disorders are complex traits and the 
affecting mutations and their frequencies are likely to be different between and 
even within populations, so even if association with the previously identified 
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haplotype is not found, the gene can not be excluded from the aetiology of the 
disorder in the replication sample. In order to perform replication for the same 
gene as in the previous findings, multiple SNPs and their haplotypes throughout 
the gene of interest should be tested. Then, even if association is found to the 
same gene as the previous sample, the original problem of multiple testing has 
not been addressed (Figure 5). 
Figure 5 
Illustration of the two methods that can be used to try and replicate an 
association finding with an allelic haplotype. Style a) replicates everything 
performed in the original analysis, and observes association to the trait with a 
different allelic haplotype, whereas style b) replicates only the positive finding 
from the original analysis and risks not detecting association from elsewhere in 
the same gene. 
For association and haplotype analysis of schizophrenia the latter approach has 
generally been taken. Both the NRG1 and DTNBP1 genes have displayed an 
initial association to schizophrenia that has since been replicated. In most cases 
this replication has emerged from association data of a haplotype different or 
derived from the one initially presented. Therefore, if only the original 
haplotypes had been tested as replications in these independent samples then the 
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observed associations would have been missed and the support for these two 
candidate susceptibility genes would not be as convincing as it is today. 
Therefore, researchers should continue to define the full spectrum of allelic 
variation at previously associating loci, yet contribute to an accumulating 
replication that will eventually lead to the gene being confirmed or dismissed for 
involvement in the aetiology of the disorder. Given guidelines would need to be 
based on the probability of a number of independent groups observing 
association at the locus using multiple tests, given that the association is a false 
discovery133.
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3 Aims of the study 
The general aim of the study presented here has been to progress the work on the 
genetic risk factors that underlie the mental illness schizophrenia, using the 
unique nationwide study sample collected from Finland. It was intended that by 
focusing on a single genomic region that had multiple lines of evidence for its 
involvement in the disorder, the study would use a three step strategy, with each 
step concluding on a different aspect of the genetic aetiology of the disorder. 
Validation: To determine the significance of the previously identified linkage 
findings for schizophrenia on chromosome 1q, through independent replication 
using Finnish families ascertained for schizophrenia. 
Dissection: To use the candidate gene approach on a locus highlighted by 
significant linkage to identify genetic variations that associate with 
schizophrenia, and to relate any observations to the aetiology of the disorder 
through the use of qualitative trait components and quantitative endophenotypes. 
Utilisation: To use any consistently observed associations as a conditioned factor 
in a genome-wide scan, in order to identify additional genomic loci that may 
play a role in the aetiology of schizophrenia. To be followed by the further 
dissection of any potentially linked region, in order to additionally discern its 
role in schizophrenia. 
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4 Materials and methods 
4.1 Table of materials and methods 
The details of the materials and methods used in this study can be found in the 
original publications according to Table 5. 
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Table 5 
Material or Method Original Publication 
Sample Materials  
Finnish Schizophrenia Family Sample I-IV 
Linkage Replication sub-sample I 
Internal Isolate sub-sample II 
All Finland sub-sample II 
Quantitative Trait sub-sample III-IV 
HEP3 Stratified sub-samples IV 
Control sample III-IV 
Phenotype Methods  
DSM-IV Consensus Diagnosis I-IV 
Increasingly Inclusive Liability Classes I-IV 
OCCPI Trait Components  II 
Neurocognitive Traits III-IV 
Transformation of Traits III 
Covariates III-IV 
Statistical Methods  
Marker and SNP Selection I-II, IV 
Genotype Correction I-II, IV 
Two-Point Linkage I, IV 
Multipoint Linkage I 
Simulation of Linkage IV 
SNP Association I-II, IV 
Haplotype Association I-IV 
Permutation of Association I-IV 
Bonferroni Correction IV 
Haplotype Construction III-IV 
Laboratory Methods  
Genotyping I-II, IV 
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4.2 Study samples 
4.2.1 Schizophrenia family sample 
The samples used here have been collected as part of a wider project that has 
provided the ground work on which this study is based. Collection of this sample 
started in the late 1980s and in its current form is an extension of the samples 
previously used to perform linkage analysis for schizophrenia in 
Finland7,32,88,105,134. The sample identification and collection has remained the same 
throughout the years, where Finnish patients with schizophrenia born between 
1940 and 1976 were identified through the hospital discharge, disability pension, 
and the free medication registers. Close family members of each proband where 
then identified through the national population register, enabling the 
construction of pedigrees134,135 (Figure 6). 
Figure 6 
Schematic of the methods used for identifying probands affected with 
schizophrenia, for the collection of the study material used in all stages of this 
research. 
The whole sample used in this study now totals 458 families consisting of 498 
nuclear families that contain 2,756 individuals, of which 2,059 have been 
genotyped. Of these genotyped individuals, 931 are classified as affected using 
increasingly inclusive liability classes (LC) using criteria from the Diagnostic 
and Statistical Manual of Mental Disorders, forth edition (DSM-IV)28. LC 1 
constitutes schizophrenia only, LC 2 added those individuals affected with 
schizoaffective disorder, LC 3 added individuals with schizophrenia spectrum 
disorder136 (schizoid, schizotypal and paranoid personality disorder, 
schizophreniform, delusional and brief psychotic disorder, and psychosis not 
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otherwise specified), and LC 4 added individuals with bipolar affective disorder 
or major depressive disorder, with and without the presence of psychosis. 
For parts of this study it was necessary to divide this large family material of 
458 families into the sub-samples described here; 
Linkage Replication sub-sample: Since the original publications of observed 
linkages on chromosome 1q in the Finnish family samples, the identification and 
collection of new families has continued. Therefore, there were an additional 81 
families that could be used for further analysis and yet be independent of the 
previous observations. These 81 families consist of 501 individuals, of which 
180 are classified as affected under LC 4. However, for linkage replication 
purposes the liability class where the best previous linkage was observed was to 
be used (LC 3). This resulted in 70 linkage informative families with 79 LC 3 
affected sib-pairs. 
Geographical sub-samples: The entire sample set could be divided into two sub-
samples that are defined by the geographical origin of the family. The first sub-
sample contains the families obtained from the young internal isolate population 
(IS) used in the genome-wide scan that showed linkage on chromosome 1q32-
41105. This sample now consists of 179 families, made up of 1,137 individuals. 
The second sub-sample contains families obtained from the whole of Finland 
(AF), exclusive of the internal isolate, that displayed linkage on chromosome 
1q427. This sample now consists of 279 families, made up of 1,619 individuals. 
There is no overlap between these two groups and when they are analysed 
together they combine to create the whole sample. 
Quantitative Trait sub-sample: Due to the extensive nature of the traits being 
measured for quantitative analysis it was only logistically feasible to test 
approximately half of the families from the entire sample. This sub-sample 
consists of 215 families containing 1,437 individuals of which 400 are classified 
as affected, and where 746 have undergone extensive neuropsychological 
assessment, including 356 offspring currently unaffected under LC 4. 
HEP3 Stratified sub-samples: Schizophrenia is commonly accepted to be a 
polygenic disorder. Therefore in order to detect other potential susceptibility loci 
for the disorder the entire sample was stratified based on the HEP3 haplotype. 
HEP3 is a haplotype of DISC1 identified to associate with schizophrenia through 
the analysis performed in stage II. The original study of 458 families was split 
into those families where at least one family member was predicted to have the 
HEP3 haplotye (n = 145) and those where no one in the family was predicted to 
have the HEP3 haplotype (n = 313). Only the predicted haplotypes of family 
members that had been genotyped were considered when making the dissection. 
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The two separated sample sets would then potentially be more genetically 
homogeneous than when they are combined, leading to the ability to further 
detect other prospective genetic factors influencing the aetiology of 
schizophrenia in this study population. 
4.2.2 Control sample 
In stages III and IV a sample of 60 anonymous Finnish trios, representing a 
random sample of the population was used in order to derive the unbiased 
frequencies of the HEP3 haplotype. Additionally in stage IV, this sample was 
combined to the whole sample for association analysis, to partially account for 
the ascertainment bias of the family sample. 
4.3 Ascertainment of phenotypes 
4.3.1 Clinical diagnosis 
The diagnostic assessment used for the entire sample population is based on the 
analysis of all available inpatient and outpatient records for those individuals 
with a register based diagnosis of psychosis between 1969 and 1998, which were 
born between 1940 and 1976. Two psychiatrists then independently determined 
the consensus best estimate lifetime diagnosis, based on all available case 
reports, according to the DSM-IV, blind to family structure and register 
diagnosis. If these two psychiatrists provided conflicting diagnoses a third 
independent psychiatrist was used to reach the consensus. Reviewer agreement 
on the diagnosis has been noted to be excellent, with kappa values ranging from 
95% to 99% depending on the liability class137. This method for determining the 
individual diagnoses has repeatedly been shown to be reliable12,138,139.
4.3.2 Operational criteria checklist for psychotic illness 
In addition to the consensus diagnosis made according to the DSM-IV criteria, 
one reviewer completed the Operational Criteria Checklist for Psychotic Illness 
(OCCPI). The OCCPI checklist consists of 90 items of psychopathology, pre-
morbid functioning, and personal history69,70. Factor analysis had been performed 
for 30 of the 90 OCCPI items from 190 patients with schizophrenia from the IS 
population and 466 affected sib-pairs from the AF sample. It was found that 24 
of these 30 items segregate into four factors: factor 1 “delusions and 
hallucinations”, factor 2 “manic”, factor 3 “negative”, and factor 4 
“depressive”137. These factor structures were used to determine qualitative trait 
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phenotypes for use in stage II, where at least one of the items loading > 0.5 had 
to be present in the individual to count them as positive for that factor. If any of 
the 24 individual OCCPI items had more than two possibilities for classification, 
then these were also converted into qualitative traits by taking any score > 0 as 
meaning the individual is positive for this item. 
4.3.3 Neurocognitive variables 
The neuropsychological test battery, from where the quantitative 
neurocognitive traits were obtained, is a series of tests that uses well 
validated, internationally used neuropsychological instruments to evaluate an 
individual’s cognitive ability. These tests have previously been shown to be 
endophenotypes for schizophrenia66,140,141, with other endophenotypes not 
being collected as the tests were to be performed in the field. The test 
includes the Wechsler Memory Scale - revised (WMS-R)142, the California 
Verbal Learning Test (CVLT)143, and the Wechsler Adult Intelligence Scale - 
Revised (WAIS-R)144. They were administered to the subjects in a fixed order 
by experienced psychologists or psychiatric nurses who had received 
extensive training with the test battery, and all scoring was done by 
experienced psychologists66. In stage III the Visual Span forward and 
backward subtests of the WMS-R were used to assess visual attention and visual 
working memory respectively. Verbal learning and memory were assessed 
using the California Verbal Learning Test. From this test, using semantic 
clusters as a learning strategy, and the intrusive recall errors score, were 
logarithmically transformed to reach normality for the analyses. In stage IV 
only the visual working memory trait was used for analysis. 
4.4 Laboratory methods 
4.4.1 Sample collection and DNA extraction 
For each consenting individual 20 - 30 ml of blood was drawn into EDTA tubes, 
from which DNA was extracted according to the standard procedure established 
by Blin and Stafford145.
4.4.2 Genotyping
For the linkage analysis in stages I and IV microsatellite markers had been 
genotyped by ABI 377 automated DNA sequencer (Applied Biosystems). For 
stages I to IV SNPs were used for association analysis, these were either 
identified from contig alignments, from EST alignments or by sequencing for 
the DISC1 locus, or from public databases for both the DISC1 and NDE1 loci. 
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Potential SNPs not located by sequencing were verified in 12 Finnish controls. 
In stage I and II the resulting 28 SNPs at 1q42 were genotyped in the entire 
sample using TaqMan (Applied Biosystems), solid-phase mini-sequencing146 or 
by using array based genotyping147. In stages III and IV SNPs were genotyped 
using the Sequenom MassARRAY system148.
4.5 Statistical methods 
All microsatellite and SNP markers used in this study were checked and 
corrected for Mendelian errors prior to analysis using the Pedcheck program123,
and for non-Mendelian errors using the MENDEL program124. If such an error 
was observed then the genotypes for that marker in the whole family were 
removed.
4.5.1 Linkage analysis 
The linkage analysis of each marker individually (two-point) assuming a model 
for genetic heterogeneity in stage I and IV was performed using the MLINK 
program from FASTLINK 4.1P version of the LINKAGE package149-153. The 
additional multipoint analysis of stage I being performed using the LINKMAP 
and HOMOG programs conditional on the marker-marker haplotype frequencies 
estimated with a specially written version of the ILINK program. Simulation of 
the linkage significance in stage IV was carried out by randomly reassigning 
genotypes to individuals, but keeping the genotype frequencies identical to the 
original analysis, to create 100 random replicates of the sample using the 
SIMULATE program154,155. Linkage analysis, as performed for the original 
sample, was performed on each of these replicates by using a modified version 
of the automated genome-wide linkage program AUTOGSCAN156, with the 
derived p-values being calculated from the number of times the observed lod 
score was seen or exceeded in these simulations. The derivation of the p-value 
was performed across all scans, across all scans in each sample, and for each 
individual scan. 
4.5.2 Association analysis 
For stages I, II and IV two-point analysis was performed using the 
Pseudomarker program, which performs joint linkage and linkage disequilibrium 
(LD) analysis on a mixture of pedigrees and singletons. Pseudomarker is able to 
combine the power of linkage analysis with that of association, and can test for 
LD in general pedigrees conditional on linkage. The latter is used when it is 
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known that the sample already displays linkage to a particular region being 
analyzed for association157. Once two-point analysis had been performed on the 
SNPs the analysis of haplotypes was performed, using the TRANSMIT program. 
This software is able to test for transmission of a haplotype even when phase is 
unknown and when parental genotypes are not completely known. The 
TRANSMIT program is also able to compensate for the presence of linkage 
when using family data by the calculation of a robust variance estimate125.
Haplotypes below a sample frequency of 3% were aggregated and counted as 
one haplotype when calculating the global p-value, but were ignored as being 
too rare as individual haplotypes. TRANSMIT performed 100, 000 bootstrap 
tests for all analyses, from which it derived the empirical p-values. As additional 
checks of the quality of the findings with the TRANSMIT program the analysis 
with any associating haplotypes was re-run with two conditions. First, only those 
families where complete genotype information was available were used in order 
to eliminate any false positive results based on the corrections for missing data. 
Secondly, the analysis was run 20 times taking randomly one affected individual 
per nuclear family, in order to completely eliminate any linkage affects on the 
association. For stage II Pseudomarker analysis was performed for all SNPs in 
all LC phenotypes using all three samples. However, TRANSMIT analysis was 
performed originally in the whole sample using only LC 4 to locate any 
significant haplotypes (p < 0.05), which were then tested in all of the phenotypes 
with all samples. In stage I analysis was only performed using the SNPs where 
linkage had previously been observed, and their flanking SNPs. For stage III and 
IV the TRANSMIT program was used in the same way to see how the reduced 
sample size from only using those families with quantitative trait information, 
affected the ability to detect the previously observed associations. In stage IV 
both Pseudomarker and TRANSMIT analysis was performed only using LC 4, 
with multiple testing being corrected for by using the over conservative 
Bonferroni method. 
4.5.3 Haplotype construction 
In stages III and IV it was necessary to determine the haplotypes for all 
genotyped individuals, yet there was no gold standard method available for 
performing this on data that consists of multiple tightly linked SNPs in a family 
based material. The most reliable way to construct these haplotypes with this 
data set was to use the Simwalk2 program120, a Markov chain Monte Carlo 
(MCMC) and simulated annealing program for haplotype analysis. In order to 
increase the reliability of the predicted haplotypes, all possible markers that had 
been genotyped in the 1q42 and 16p13 regions were used, which included 28 
SNPs and 4 microsatellite markers for 1q42, and 7 SNPs and 2 microsatellite 
markers for 16p13, with the entire sample of 458 families being used. The 
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frequencies of the resulting haplotypes were identical to those estimated from 
the genotypes by TRANSMIT. In stage IV the selection of which SNPs to 
include in the haplotype analysis was governed by testing for linkage 
disequilibrium between the genotyped variants. This was done by analysing the 
founder genotypes using the Haploview program158, this compares each set of 
neighbouring markers to see how much of one marker can be defined by the 
other marker. Using the “solid spine of LD” criteria from this program 
highlighted the four SNPs that would “tag” for the whole region when analysed 
as a haplotype. 
4.5.4 Quantitative trait analysis 
In stages III and IV a direct test for transmission distortion between a haplotype 
and a quantitative trait was to be tested. The haplotypes were constructed using 
Simwalk2, as previously described, and the resulting haplotypes were recoded to 
form “bi-allelic markers” so as to allow the hypothesised haplotype risk allele to 
be tested against all other possible haplotype alleles combined. These were used 
within the QTDT program129. This is a variance component method for testing 
for transmission distortion of an allele with a quantitative trait. In the analysis, 
age, sex, and affection according to LC 4 were used as covariates, and 100, 000 
permutations were performed to derive the empirical p-values. 
4.6 Ethical considerations 
Schizophrenia presents in signs and symptoms within the entire range of human 
mental activity, damaging functions regarded as specifically human. This makes 
the disorder highly stigmatizing to the subjects, their families, and the 
community. Therefore, the importance of confidentiality is primary in research 
into the disorder. In these studies, the principles recommended in the 1964 
World Medical Association Declaration of Helsinki, and its amendments, were 
followed. The research was approved by the Ministry of Social Affairs and 
Health (Finland) and the appropriate institutional review boards, and written 
informed consent was obtained from all individuals. In effect this meant that all 
identification of the individuals who have graciously donated DNA samples to 
this research was through the use of numeric codes. Such a code allows for 
anonymous analysis by all researchers using this sample set, with only a couple 
of senior researchers possessing access to the password protected database 
containing the key to the code. Additionally, this database is only located on an 
internal institute network, secured by a firewall and data encryption. 
Furthermore, sensitive data is not allowed to be stored on laptops, portable data 
transfer media, or printed. 
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5 Results and discussion 
5.1 Validation of the 1q42 locus in schizophrenia 
Linkage analysis of schizophrenia has highlighted a number of interesting 
regions on chromosome 13,5,8,77,80,107, two of which have been identified in samples 
ascertained from the Finnish population. In a study of an internal isolate 
population a haplotype spanning from 1q32 to 1q41 was identified105, and 
markers on the 1q42 region were observed to be linked to schizophrenia in the 
study sample of 168 Finnish families exclusive of this internal isolate7.
Since these studies the sample material for the analysis of schizophrenia in 
Finland has been expanded, with the addition of 70 families containing a total of 
79 affected sib pairs (ASPs). Initially this new independent sample was to be 
used to study chromosome 1 in order to verify through replication the genomic 
regions that had been previously linked to the disorder. A dense set of 300 
polymorphic markers were analysed including all the microsatellites that had 
been previously used in the two prior analyses of schizophrenia in Finland7,105,
with the density of markers being concentrated around these two Finnish 
findings at 1q32 and 1q42. Two-point and multipoint linkage analysis was 
performed for all markers, and as some of the markers were SNPs, two-point and 
haplotype association analysis was performed for those providing evidence of 
linkage.
Linkage was observed at the 1q42 locus (Figure 7) using a dominant affected 
only model for LC 3. The best two point lod score (lod = 2.70) was obtained for 
a SNP located within intron 9 of the DISC1 gene (rs1000731). A neighbouring 
SNP 1.5 kb towards the centromere (rs3890280) also provided some evidence 
for linkage (lod = 2.30) (I). The SNP rs1000731 is located only 67 kb from the 
microsatellite marker D1S2709 that provided the strongest evidence for linkage 
in the previous Finnish finding on 1q427.
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Figure 7 
Graph of two-point linkage findings on chromosome 1q, showing linkage observations with respect to the previously 
published findings on this chromosome. 
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Two-, three- and four-marker haplotype association analysis was performed for 
the two most significantly linked markers and their two flanking SNPs (Figure 
8). Two-point association analysis, conditional on the presence of linkage, 
displayed little evidence of association, (rs751229, p = 0.022; rs3890280, p = 
0.20; rs1000731, p = 0.090). Additionally, the two-marker haplotype containing 
only the two most strongly linked SNPs did not provide evidence of association 
(p = 0.31). However, a three marker haplotype containing the SNP rs751229 in 
addition to these two SNPs provided significant association (p = 0.00090), being 
over-transmitted to affected individuals (I). 
Figure 8 
Graph to show the empirical p-values from the association test using haplotypes 
of four SNPs located in intron 9 of DISC1 on 1q42. Style adapted from Schwab 
et al23
For the 1q42 genomic region, the most likely candidate genes are DISC1 and 2,
with the best evidence from three independent studies being intragenic of these 
genes3,7(I), with a further two showing linkage in the promoter region of 
DISC15,8. This would appear to contradict the evidence from simulation studies 
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demonstrating poor resolution of linkage peaks in the efforts to position a 
complex disease gene134,159. However, although weak evidence of association was 
observed for markers under this linkage peak, it cannot be excluded that nearby 
susceptibility variants are partly or wholly responsible for the observed linkage 
signals.
The microsatellite marker D1S2709 that provided the original observation of 
linkage at 1q42 in the Finnish population failed to show significance in this new 
study sample (two-point lod = 1.00) (I). So, although the study sample was from 
the same Finnish population, replication would not have been obtained using the 
same set of microsatellite markers, and it was only by using a denser marker 
map and by including SNPs, that evidence for linkage was observed that clearly 
exceeded the genome-wide replication threshold (point-wise p of 0.01 ~lod 1.18) 
suggested by Lander and Kruglyak116. This underlines difficulties involved in 
interpretation of linkage findings in complex traits, and brings additional queries 
to the validity of a previous attempt to replicate linkage on chromosome 1q 
using only 16 microsatellite markers109. As here linkage was only detectable 
using a very dense marker set, and would not have been observed if only the 16 
markers used in the multi-centre study would have been used. 
5.2 Dissection of the 1q42 locus in schizophrenia 
To further analyse the 1q42 locus, 28 SNPs located within 600 kb were 
monitored for two-point and haplotype association to schizophrenia, in the entire 
sample material available. Two-point analysis showed that one SNP 
(rs3737597), with a minor allele frequency of 2%, located in DISC1 exon 13 
displayed consistent suggestive association with schizophrenia, displaying a p-
value of 0.0021 (Chi square = 9.44, 1 df) for LC 2, but also displaying p-values 
< 0.01 for the other liability classes (II). 
Haplotype analysis was performed for the whole region using the broadest 
phenotype (LC 4), in order to include all possible phase information and 
statistical power of the sample, and used the sliding window technique of 
systematically taking two to three neighbouring SNPs in turn for the analysis. 
One haplotype (HEP1) was observed to be significantly over-transmitted (p = 
0.00045) to affected individuals, and is the haplotype identified in the replication 
of the original linkage finding (I). Three other haplotypes displayed significant 
under-transmission to affected individuals. The first (HEP2, p < 0.000010) was 
located within the TRAX gene, while the other two (HEP3, p = 0.0031; HEP4, p 
= 0.00057) were both located in DISC1 (Figure 9) (II). Further, the HEP3 
haplotype displayed significant evidence for under-transmission only to affected 
females (p = 0.00024) compared with under-transmission to affected males (p = 
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0.38). While, for HEP4 the TRANSMIT program predicted that these SNPs 
would only produce two haplotypes. Consequently, the alternative haplotype 
was over-transmitted with a significant p-value of 0.00057, but was ignored by 
the TRANSMIT program due to a sample frequency below 3%. Therefore, 
within the six SNPs located in DISC1 exon 13, associations were observed for a 
single SNP (rs3737597) and a number of 2 SNP haplotypes (II), but as all 
associations seen in this region involve rare polymorphisms (sample frequency < 
3%) conclusions should be drawn with caution. 
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Figure 9 
Schematic diagram to show the relative locations of the two-point association and the four identified haplotypes on 
chromosome 1q42. The exonic structure of TRAX (grey boxes), and the DISC genes (black boxes) are also shown in 
relationship to the intergenic exons (white boxes). 
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Two validation tests for these findings were performed using the three common 
haplotypes (HEP1, HEP2, and HEP3), to ensure that these findings are true, and 
do not represent linkage or errors caused by estimation of the missing data. 
Initially the transmission distortion of these haplotypes was analysed in only 
those families where both parents were genotyped (n = 147 nuclear families). 
Only HEP3 continued to display the statistical significance already observed (p 
= 0.00084), but although evidence for sex differences in transmission distortion 
remained, this difference was not as significant as in the complete study sample 
of 458 families (Female, p = 0.0020; Male, p = 0.018). Tests randomly taking 
only one affected offspring per family were additionally performed. This was 
carried out 20 times for each haplotype taking the mean value of these as the 
average. Only HEP1 displayed no significance (p = 0.17), while both HEP2 (p = 
0.0040) and HEP3 (p = 0.035) still showed some association to the LC 4 
phenotype, with HEP3 still displaying sex dependent differences in transmission 
(Female, p = 0.0065; Male, p = 0.38) (II). 
Throughout these analyses, the HEP3 haplotype appeared to represent the most 
robust finding. This haplotype spans 62 kb from intron 1 to exon 2 of DISC1,
highlighting the gene as contributing to the aetiology of schizophrenia. With the 
observed sex differences in the association putatively implying that this genetic 
region could contribute to the sex differences found in the schizophrenia 
phenotype36,45,46,160. Mechanisms for sex differences, such as imprinting161 and 
hormonal effects162, can biologically present in gene expression. 
The haplotype HEP2 is located within intron 4 of TRAX and displays levels of 
significance similar to that of the HEP3 finding, and in the same pattern for all 
tests except one. When HEP2 was tested in only those families with complete 
genotype information no significant association was observed. Despite this the 
other association findings with HEP2 indicate that it is still worth investigating 
further. In contrast, when the HEP1 haplotype was analyzed for association 
using complete families or randomly selected trios no further evidence was 
observed, suggesting that this finding may be due to the previously observed 
linkage findings in this localised region. 
To extend the analysis of the role of these three putatively associated haplotypes 
they were tested further by analyzing trait components as well as the end state 
diagnosis, using the remaining three liability classes, the four factor groups, and 
the 24 OCCPI items. HEP1 was found not to show further associations to any 
other phenotype or sub-sample. While, in the analysis of the sub-samples, both 
HEP2 and HEP3 were significantly associated only within the AF population, 
with no suggestive results being seen in the IS sample (II). This is consistent 
with previous findings that have observed linkage with the AF population to 
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1q42, while the IS population displays linkage to 1q32-417,105. Analysis of HEP2 
and female specific HEP3 using the component traits, showed that these 
haplotypes mainly associate to traits representing delusions, hallucinations, and 
negative symptoms (II). Yet, as trait-components are highly dependent upon the 
end-state diagnosis, then it is possible that the associations observed with these 
traits are really a reflection of the association already observed with 
schizophrenia. However, it is well characterized that more severe negative 
symptoms in individuals with schizophrenia correlates with poorer cognitive 
ability163. Therefore in order to take analysis of the 1q42 locus further, the two 
most consistent haplotypes (HEP2 and HEP3) were tested with five traits of 
neurocognitive ability that had previously been shown to be linked to the 
TRAX/DISC neighbouring region 1q4110,106.
Endophenotype analysis was carried out in a sub-sample of the original analysis 
in which 746 individuals were assessed with a neuropsychological test battery. 
To evaluate the effect of the reduced sample size on the ability to detect the 
original association with these haplotypes, analysis using the same program and 
specifications from the original finding (II) was performed, within this 
extensively phenotyped sample. Despite the reduction in sample size the 
association signal, in relation to schizophrenia diagnosis for both HEP2 and 
HEP3 remained at the suggestive level (p = 0.0082 and 0.072 respectively) (III). 
Next, association analysis of the HEP2 and HEP3 haplotypes was carried out 
using the quantitative neuropsychological test variables: visual working 
memory, visual attention, verbal learning and memory, using semantic clusters 
as a learning strategy, and intrusive recall errors. It can be hypothesized that the 
use of more informative quantitative traits, if truly associated with clinical 
vulnerability and the studied gene variations, has the potential to display 
stronger association. The haplotype HEP3 displayed up to 50-fold more 
significant association to the traits of visual attention and working memory, with 
p-values 0.0079 and 0.0013 respectively, than to schizophrenia, but did not show 
association to any of the three traits of verbal learning and memory (III). The 
haplotype HEP2 showed no association to any of the five traits tested. In order to 
determine whether these associations are primarily to the trait itself or rather 
reflects the effect of schizophrenia on the trait distribution, the association 
between HEP3 and the two traits of visual memory functions was analysed 
separately for affected and unaffected individuals. Only for visual working 
memory did both affected and unaffected individuals contribute to the observed 
association in the combined study sample, p-values 0.034 and 0.048 respectively 
(Table 6). Furthermore, in analysis with affection status HEP3 displayed sex 
differences in its transmission distortion, only being significantly under-
transmitted to affected females. In order to investigate if similar sex dependent 
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effects were present in the association to these quantitative traits the analysis 
was repeated, once only including male offspring and then only including female 
offspring. The association to the visual working memory trait was only 
significant in males (males, p = 0.0060; females, p > 0.10) (Table 6) (III).
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Table 6 
Empirical p-value results from analysis of the two haplotypes and LC 4 or the two quantitative traits of visual 
memory functions used in this study. 
a
 Analysis using only male offspring 
b
 Analysis using only female offspring 
c Analysis using only offspring affected under LC 4 
d Analysis using only offspring currently unaffected under LC 4
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Although the results of this study support the hypothesis that DISC1 associates 
with visual working memory and attention, the finding that HEP3 associates 
with poorer performance appears counter intuitive. The HEP3 haplotype was 
observed to be under-transmitted to affected individuals. Unaffected individuals, 
when compared to individuals with schizophrenia, have better performance in 
both visual attention and visual working memory. Yet the HEP3 haplotype does 
not associate with superior but rather with poorer performance. In addition there 
is the complication that the observed associations each have sex dependence, 
being only to females when analysing the end state diagnosis, and only to males 
when analysing visual working memory. 
It was therefore necessary to re-evaluate the original finding of association to 
schizophrenia. To this end, the two SNPs that constitute the HEP3 haplotype 
(rs751229, rs3738401) were genotyped in a group of 60 control trios, 
representing anonymous samples from the Finnish population. From this sample 
set the HEP3 haplotype and transmission frequencies were determined, which 
were lower than in the schizophrenia family sample (Table 7). Using a Chi-
square test, the relationship between the observed number of transmissions to 
affected individuals in the whole sample and the expected number were re-
examined based on the transmission frequencies from the control trio sample 
(Table 8). Although this analysis has less power for the detection of association 
it would be indicative of the type of results expected to be observed by analysis 
similar to the one performed by the higher power TRANSMIT program, but 
using allele frequencies determined in a control population. These results 
suggest that due to HEP3 having a higher frequency in the schizophrenia sample 
than controls, the original number of expected transmissions was upwardly 
biased, which in turn led to the epiphenomenon of the observed under-
transmission to affected females. In the light of the present results a more 
parsimonious interpretation of the data would be that the HEP3 haplotype 
actually confers risk to males in this study population, and that this risk affects 
schizophrenia and its related disorders through a role in visual working memory. 
54
Table 7 
Haplotype and observed transmission frequencies of the HEP3 haplotype in a control sample and the whole sample. 
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Table 8 
Re-examination of the difference between the observed and expected number of transmissions to affected offspring in 
the whole sample. a) The original observation. b) Using an expected transmission frequency based on that of a control 
sample.
In the whole sample there were 1678 transmissions to affected offspring, of which 1006 
were to males and 672 to females. 
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5.3 Utilisation of the 1q42 locus to identify additional loci in 
schizophrenia 
It is generally accepted that schizophrenia is a polygenic disorder, and the 
concept that identification of the first candidate gene would greatly facilitate the 
identification of others has been proposed. The genome-wide scan data from the 
whole sample was analyzed ascertained for the presence of the DISC1 HEP3 
haplotype in each family. Although from the earlier findings (II, III) it would be 
possible to hypothesise about the causative mechanism represented by HEP3, a 
more conservative criterion for dividing the sample population was used. The 
original study of 458 families was split into those families where at least one 
family member was predicted to have the HEP3 allelic haplotye (n = 145 
families) and those where no one in the family was predicted to have the HEP3 
allelic haplotype (n = 313 families). It can be hypothesized that since locus 
heterogeneity certainly exists between families this ascertainment strategy could 
provide some added power to identify genes involved in the molecular 
pathogenesis of schizophrenia. 
Genome-wide data from 443 microsatellite markers was analysed in the 
resulting two samples and the whole data set. With these analyses being 
performed in all four increasingly inclusive liability classes, and using both 
dominant and recessive models. This meant that a total of 24 genome scans were 
being tested and therefore, simulation was essential in order to derive the 
significance of any findings in the face of such multiple testing, and to account 
for the additional biasing caused by the conditioned separation. This was 
performed by simulating the genotypes for the whole sample 100 times, and then 
performing all analyses for the separate samples and models for each replicate. 
This simulation was also used to show that the sample sets linkage information 
content do not greatly differ, ensuring that one sample was not liable to provide 
over-inflated lod scores of no significance (Figure 10). 
Most of the study sample represented families that were used for the previous 
published Finnish genome-wide scans for schizophrenia7,32,88,105, but also 
contained new families that have been collected as an extension of those studies 
(I). When the complete study sample (n = 458) was used in the linkage analysis 
across the eight models tested, evidence for linkage (lod > 3) emerged for two 
genomic loci: D1S2709 (lod = 3.64) located at 1q42 intragenic of the DISC1
gene, and D5S647 on 5q12.3 (IV). The 1q42 locus was the region where linkage  
had previously been observed in the Finnish family study sample7(I), and here 
the most significant linkage was also displayed under the dominant model of LC 
3 as was seen in these original analyses. The marker D5S647 is located 71 cM 
from the previously observed linkage on 5q33 in the Finnish population88, but is 
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within the chromosome 5q11-q13 region originally implicated in Icelandic, UK 
and Canadian study samples in 198813,14.
Once the sample had been conditioned for the HEP3 haplotype, three loci 
provided evidence for linkage (lod > 3): 1q42 (D1S2709; lod = 3.31), 10q21 
(GATA101E02; lod = 3.58) and 16p13 (D16S764; lod = 3.17) (Table 9), all 
three within the sub-sample positive for the HEP3 haplotype (n = 145 families) 
(IV). It was expected that D1S2709 would display a high lod score since this 
marker showed the initial significant linkage in Finnish families for 1q42 that 
led to the discovery of the HEP3 haplotype, on which the samples used here 
were stratified. On chromosome 16p13 two neighbouring markers displayed lod 
> 2 for the dominant model under LC 1, with one of them showing lod > 3. Most 
interestingly, this region of the genome contains a gene encoding a known 
DISC1 binding protein (NDE1)164-166. Furthermore, linkage to this locus was 
observed in Finnish bipolar disorder families167, implying the relevance of the 
DISC1 “pathway”, not just DISC1, would be important in the aetiology of 
schizophrenia, and other mental disorders. The GATA101E02 marker on 
chromosome 10 displayed its evidence of linkage under the dominant model 
with LC 4, and is located at 10q21 in virtually the same region previously found 
to display significant linkage to schizophrenia in Ashkenazi Jews50 and 
suggested in other studies48,49.
No other locus displayed linkage lod > 3 after the HEP3 conditioning, however, 
nine further loci displayed linkage lod > 2. Markers on 1p13, 2q32, 6p21, 7q22, 
8p22, 11q22 and 12q21 were suggested in those families with the HEP3 allele, 
and markers on 5q12 and 8q24 were observed in the families negative for HEP3 
(Table 9) (IV). Of all these 12 loci, 8 are located at or around 20 cM from 
genomic regions previously identified in linkage studies of schizophrenia (Table 
9), and include the loci for the DTNBP1 (6p21)24, NRG1 (8p22)42, GRM334 and 
RELN31 (7q22) (Figure 11) genes that have all been associated to schizophrenia 
(for review see ref1).
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Table 9 
Significance of the lod scores > 2 observed in the two stratified sub-samples, derived from the simulation of the 
analyses performed. Additionally showing the locations of the nearest previous schizophrenia linkage findings where 
appropriate.
a2 b3-9 c2,10 d13,14 e2,22-27 f31-34 g40-44 h48-51 i3,49 j 54 k23,24,27,60-64 l42-44,67,68 
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Figure 10 
Histogram to show the linkage information content of the three samples used here, showing the significance expected 
for a range of lod scores, given the number of tests performed. The thick solid black line represents the significance 
across 24 models performed. The thick dashed line represents the significance across the 8 models performed on the 
whole sample. The thin solid line represents the significance across the 8 models performed on the sample of families 
who did not carry the HEP3 haplotype, and the thin dashed line represents the significance across the 8 models 
performed on the sample of families with the HEP3 haplotype. 
60
Figure 11 
Schematic diagram to highlight the primary regions of interest indicated by 
performing a genome-wide scan conditional on a DISC1 haplotype. Locations of 
the microsatellite markers that provide the evidence of linkage are indicated with 
downward pointing arrows. Thick black lines above each chromosome represent 
previous linkage findings and thick black lines below represent previous 
association findings. All schematics show 40 Mb, with relevant genes illustrated 
for each chromosome. 
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By controlling for DISC1 status in a large nationwide collection of Finnish 
schizophrenia families it was possible to detect linkage to several loci containing 
previously identified candidate genes, not observed in the whole sample. This 
finding would provide some support to the hypothesis that several of the 
associated candidate genes reported actually work in concert. Therefore, such an 
approach could guide the gene identification efforts in other study samples and 
hopefully facilitate formulation of a comprehensive model of the complex 
genetic background of schizophrenia. 
However, the observed pattern of linkage raises an important question about the 
linkage results presented here. In all three sample sets analyzed, the average 
number of individuals per family was approximately equal (n = 6), as was the 
average number of affected individuals per family (n = 2). Additionally, it was 
shown through simulation that all three sample sets were of approximately equal 
information content for linkage (Figure 10). Therefore, an equal number of lod 
scores > 3 and lod scores > 2 in each of the three samples should have been 
observed. Yet this was not the case as we noted a total of 10 loci in the families 
carrying the HEP3 haplotype, and only 2 loci in the families which did not carry 
the haplotype. With 6 of these loci also being observed when these two samples 
are combined into the whole sample. This would suggest that there is something 
in the stratification that underlies the bias towards observing linkage in one 
sample and not the other. With that strategy ultimately representing the role of 
DISC1 in the aetiology of schizophrenia, a number of potential hypotheses can 
be implicated. Initially, it would suggest that the sample families where HEP3 
has been identified as a risk factor could have a higher genetic liability to this 
complex disorder for which they are potentially more homogeneous, and that in 
those families where other genetic factors act without the DISC1 risk allele, a 
greater number of environmental risks may be acting. However, such a 
hypothesis based on this observation may remain theoretical until more is 
determined about the causes of schizophrenia. 
The linkage on 16p13 immediately implicated the potential involvement of the 
NDE1 gene, since the corresponding polypeptide has been shown to bind to the 
DISC1 protein164-166. Seven SNPs over the 75 kb of the NDE1 gene were 
genotyped and analyzed along with their corresponding haplotype consisting of 
four SNPs that “tag” for this gene. Only 2 SNPs (Table 10) and the tag-
haplotype (Table 11) displayed association < 0.05, although neither the SNPs 
nor the haplotype were significant after Bonferroni correction for the 8 tests 
performed at this stage (IV). As the observation of association to DISC1 had 
displayed sex dependent effects it was tested if such effects may also affect the 
association with the NDE1 gene, since it is encoding a protein with an 
established biological connection with DISC1. Such an effect was observed, 
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with all SNPs (Table 10) and the tag-haplotype (Table 11) displaying p-values < 
0.05 only for female offspring. After correction for multiple testing the 
association observed with the tag-haplotype (p = 0.00046) remained significant 
(p = 0.011) for the total 24 tests performed (IV). The risk allele of the tag-
haplotype comprises the CGCC alleles of the SNPs rs4781678, rs2242549, 
rs881803, and rs2075512 respectively, and is present in the families ascertained 
for schizophrenia at the frequency of 30% while in the control trio sample from 
Finland it has a frequency of 19%. 
Further, as DISC1 had been shown to be associated with a neurocognitive 
measure of visual working memory in this sample, it would logically follow that 
an interacting gene may also associate to the same trait. In the analysis of 
DISC1, it was hypothesized that association to the quantitative variable, if it is 
truly associated with clinical vulnerability and the studied gene variation should 
be stronger than that to the end-state diagnosis. Such an increase was not seen 
for the NDE1 tag-haplotype, yet the analysis of only female offspring 
approached the 0.05 level of significance (Table 11) (IV). 
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Table 10 
Observed empirical p-values for the seven analyzed SNPs located within the NDE1 gene located on chromosome 
16p13. Association was tested between the genotype and the end-state diagnosis of the broadest liability class LC 4, for 
the whole sample and then separated depending on the gender of the offspring. 
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Table 11 
Empirical p-values from the analysis of the NDE1 tag-haplotype with end-state diagnosis and the neurocognitive 
variable representing visual working memory. 
a
 Analysis using only male offspring 
b
 Analysis using only female offspring 
c Analysis using only offspring affected under LC 4 
d Analysis using only offspring currently unaffected under LC 4
65
These findings would implicate that two interactive proteins, DISC1 and NDE1,
would work in concert in the genetic aetiology of schizophrenia and, potentially 
mediate some of this effect via deficits in working memory or other cognitive 
functions168,169. The currently available functional information for both DISC1
and NDE1 lend this hypothesis further credence and would expand the 
hypothesis of a “defective” pathway in functions relevant for schizophrenia. Not 
only do the proteins of these two genes interact164-166 but they also interact to form 
a complex of proteins with LIS1165, with NDE1 appearing to be interchangeable 
with its homolog NDEL1164,166. It is known that a LIS1/NDEL1 complex functions 
in neuronal migration regulated by signalling from another schizophrenia 
candidate gene, RELN (Figure 12)170. Further, mouse models with differing LIS1
heterozygous mutations have been shown to have cortical and hippocampal 
disorganization, and have impaired spatial learning and coordination171,172, while 
mouse models with NDE1 homozygous mutations have been shown to have less 
neurons in the cerebral cortex, with thin cortical layering173. Both cortex and 
hippocampus are highly implicated in schizophrenia174,175, with DISC1 having 
been shown to be additionally associated to reductions in grey matter in these 
two regions82,176. This convergence of multiple lines of evidence starts to 
implicate not just DISC1 but a “DISC1 pathway” that also incorporates NDE1,
in the aetiology of schizophrenia, potentially through underlying deficits in 
learning and memory. 
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Figure 12 
Illustration of the relationship between RELN signaling and the potential 
functions of DISC1 and NDE1 in neuronal migration with LIS1. Dashed arrows 
represent intermediate stages between the process of RELN signaling and its 
ultimate response. 
5.4 General discussion
In the beginning of this study there was only a balanced translocation that had 
been identified in a large Scottish family with major mental illness, which 
implicated not just 1q42 but also 11q14.3. The initial observation of significant 
linkage in the Finnish population concentrated the research effort to the 1q42 
locus. Observations of linkage for 1q42 to schizophrenia have since been 
observed in the Taiwanese5, and to bipolar affective disorder in a UK and 
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Icelandic sample8, and furthered with the addition of independent replication in a 
second Finnish sample (I). Linkage to the neighbouring region of 1q41 was also 
noted in two independent Finnish samples when using quantitative 
neurocognitive traits that represent cognitive ability10,106, endophenotypic traits 
that are deficient in individuals with schizophrenia and their relatives. 
Located at the 1q42 locus are two novel genes that were initially identified in 
2000. They are located on opposing strands of the genomic sequence, with both of 
them being directly disrupted by the translocation in the Scottish family. This led 
to their nomenclature assignment of Disrupted in Schizophrenia 1 and 2 (DISC1
and DISC2). Due to this, and the localisation of the observed linkage peaks in the 
Finnish family material being intragenic of DISC1, they became the prime 
candidate genes for further analysis with regard to schizophrenia. In addition, the 
Translin-Associated Factor X (TRAX) is located centromeric and in the same 
orientation as DISC1 and was identified as a further potential candidate gene when 
intergenic splicing was found to form fusion transcripts between TRAX, DISC1,
and combinations of four intragenic exons located between these two genes177. It 
has also been shown that orthologs of DISC1 are highly conserved in genomic 
structure and in its location close to the TRAX orthologs on the Mus musculus
(mouse)178 and Takifugu rubripes (pufferfish)179 genomes, implying some 
functional significance for the physical vicinity of the TRAX and DISC1 genes. 
Dissection of the biological role of these genes has greatly furthered their 
positions as candidates for a role in the aetiology of schizophrenia. Protein-
protein interaction studies show that DISC1 acts as a “scaffold” for proteins 
known to be involved in numerous neuronal functions, impacting on neurite 
outgrowth, neuronal migration, cytoskeletal modulation, and signal 
transduction164-166,180-183. The DISC2 gene is not known to encode a protein but is 
thought to act through its RNA as a regulator of DISC1107. The TRAX protein is 
known to form a brain enriched complex with Translin, that can bind single 
stranded DNA and RNA through which it is involved in protein regulation184
and, consequentially, in development and function of the nervous system. 
Since the observations in stage II of TRAX/DISC allelic haplotypes associating 
with schizophrenia, a number of independent replications have been published. In 
each case differing variants have been observed to be associated with the disorder 
in question, which includes schizophrenia4,6,9,82, schizoaffective disorder4,6, and 
bipolar affective disorder6,9.  However, two studies in the Japanese population have 
failed to find evidence to support a role for TRAX/DISC in the aetiology of 
schizophrenia185,186, although one of these studies only evaluated promoter variants 
of DISC1 rather than the full locus profile186. During the dissecting of the 
association findings with quantitative endophenotypes in stage III, an independent 
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concurrent study in a sample of Finnish twins also analysed the HEP haplotypes 
for association to a wider selection of traits derived from the same 
neuropsychological instruments as used in the family data and from magnetic 
resonance imaging (MRI) data. This study also observed association for these 
haplotypes with schizophrenia and visual working memory, and observed 
association to decreased grey matter volume in the prefrontal cortex176. It had 
previously been observed that a DISC1 SNP variant and its haplotypes associate 
with decreased grey matter volume in the hippocampus82, these two brain regions 
are those most often associated with schizophrenia174,175,187,188. Additionally, at the 
time of publication of study III, work on a further two independent studies 
simultaneously reported association between DISC1 and neurocognitive function 
in schizophrenia 169 and normal cognitive aging168.
Furthermore, by controlling for DISC1 in a genome-wide scan (IV) evidence 
was observed that other genes known to interact with DISC1 may also play a 
role in the aetiology of schizophrenia. This study highlighted a locus that had 
previously been linked to bipolar affective disorder and contained the DISC1
interacting protein NDE1. NDE1, in turn, was observed to be associated with 
schizophrenia, being over-transmitted to affected females. Upon closer look at 
the genomic localisation of other DISC1 interacting genes it is seen that there is 
existing genetic evidence for many of them to have an involvement in the 
aetiology of schizophrenia. This has come through traditional linkage analysis117,
cytogenetic analysis (Millar et al, personal communication) and linkage analysis 
using endophenotypes of schizophrenia10, as well as the linkage analysis 
performed in stage IV. Additionally, a further DISC1 interacting gene, FEZ1,
has already been shown to be associated with schizophrenia189. At the functional 
level other DISC1 binding proteins have been identified as involved in learning 
and memory functions through animal models, LIS1 in Mus musculus (mouse)190,
and PDE4B and D in Drosophila melanogaster (fruit fly)191. It has recently been 
observed that DISC1 dynamically interacts with PDE4B and D in a cAMP 
dependent manner, providing a plausible mechanistic link to learning and 
memory (Millar et al. personal communication). Therefore, all the current 
evidence is highly indicative of a “DISC1 pathway” in conferring susceptibility 
to schizophrenia potentially through a role in learning and memory functions. 
Furthermore, it is interesting to note that the complex in which LIS1 and the 
NDE1 homolog NDEL1 are known to function, and in which NDE1 and DISC1
are now hypothesised to function, in a pathway regulated through signalling of 
another schizophrenia candidate gene, RELN. Such indications of functional 
pathways in the aetiology of schizophrenia allow for more to be concluded and 
hypothesised for future analysis on how the normal workings of the human brain 
are disrupted in creating such a devastating disorder. 
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6 Concluding remarks and future prospects 
Schizophrenia is a major debilitating mental disorder that affects approximately 
1% of the worldwide population, and impacts upon the affected individual’s 
family members, communities, and the health care and welfare systems. Genetic 
analysis of schizophrenia has continued for over twenty years, yet little progress 
has been made when compared to what was expected of the field. With many 
researchers into psychiatric genetics coming to be more pragmatic as it has 
become clearer that major genes probably do not exist for mental illness, and 
that these disorders are genetically complex and heterogeneous. Yet recently a 
number of strong candidate genes have been identified that are once again 
providing hope to the field. 
Since the start of this study in September 2000 the 1q42 locus has gone from 
being just another region linked to schizophrenia, to a locus containing one of 
the hottest candidate genes for a role in the aetiology of this complex disorder. 
Primarily this transition has been due to the genetic findings presented here. 
However, the independent replication of linkage and association to this region, 
and the dissection of the protein function of DISC1 have contributed immensely 
to making this transition all the more credible. 
Yet it is Dysbindin (DTNBP1), and Neuregulin (NRG1) that can currently be 
considered to be the strongest candidate genes, with many independent 
replications after their first identification in 2002. Yet despite the convincing 
genetic evidence for all these genes it is still not possible to say conclusively if 
they function in causing susceptibility to schizophrenia. Efforts have now 
generally turned towards the identification of functional risk variations within 
these genes, when what is probably needed is a more comprehensive approach to 
the analysis. This would use numerous approaches to identify the role of the 
genes in the disorder, and would incorporate many fields of expertise, including 
animal studies, cellular expression analysis, as well as further genetic analysis. 
Once putative genetic risk variants are identified it will be possible to start to 
model how that genetic variation affects on schizophrenia when combined with 
environmental risks, putatively identifying risk factors that must either both 
occur or interact in order to create a risk to the development of schizophrenia. 
In the study presented here stage IV represents the further genetic analysis and 
presents potentially the most interesting piece of evidence for DISC1 to be 
involved in the aetiology of schizophrenia. In this stage, it was found that by 
controlling for a risk haplotype of DISC1 a region on chromosome 16 provided 
evidence of linkage that then led to the identification of association between an 
allelic haplotype of the NDE1 gene with schizophrenia. The proteins of NDE1
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and DISC1 are known to interact, potentially in the cellular processes governing 
neuronal migration. Further in silico analysis found that a number of other 
DISC1 binding proteins are genetically located in regions previously identified 
as susceptibility regions for schizophrenia, with a number of these genes having 
animal models that would implicate them in cognitive functions relevant to those 
identified as associating with DISC1. This directly implicates a DISC1
“pathway” in the aetiology of schizophrenia, which when analysed together, and 
taking into consideration their biological interactions, could provide a more 
comprehensive indication of how all these genes create to induce susceptibility 
to schizophrenia. The role of many of these proteins in neuronal migration 
would also mean that they should be studied in combination with environmental 
risk factors affecting during the time that such migration occurs, principally 
prenatal exposure to infections. 
It is this that psychiatric genetic analysis should look to next, not the 
identification of presumed unrelated genes that individually associate with 
schizophrenia, but to the identification of pathways that have a determinable role 
in the normal functioning of the human brain, through which it is possible to 
conclude upon how the disrupted pathway leads to susceptibility to 
schizophrenia. Such identified pathways will lead to a more comprehensive 
understanding of the biological aetiology that underlies the disorder. This has the 
potential not just to aide understanding of schizophrenia but also many other 
mental illnesses that potentially have overlapping or similar aetiologies. This 
would pave the way for new medications and treatments for these debilitating 
mental disorders, by being able to target specific treatments to specific 
individuals having specific deficits rather than relying on the same drugs that 
have wide-ranging non-specific affects, used for all individuals.
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